IRVINE, Calif.–(BUSINESS WIRE)–#ClinicalTrialsImmunis, Inc., a private biotech and a leading innovator in cellular secretome therapies for age and disease-related immune decline, is honored to be selected as a finalist for the “Best Emerging Technology Company” by the Octane High Tech Awards (HTA). The HTA awards recognize exceptional technology companies that have made significant contributions to their respective industries through innovation, leadership, and outstanding achievements.

During the initial judging session, the HTA team was impressed by Immunis’ groundbreaking advancements in the development of cellular secretome therapies for people with muscle atrophy associated with knee osteoarthritis (KOA). One of the most pressing challenges for individuals with KOA is regaining lost muscle mass and improving muscle function to help offset knee pain and stiffness. As there are currently no clinical treatments for mitigating muscle loss, Immunis’ cutting-edge secretome therapeutics push the envelope of healthcare technology in the hope of driving positive outcomes for KOA patients.

Immunis was one of the few companies that advanced to the final HTA judging round. In early August, HTA judges interviewed Immunis’ Chief Business Officer, Mark Cabato, after which they named Immunis an award finalist. The winners will be announced during the exclusive HTA ceremony in September.

Selecting Immunis as a finalist is a testament to the groundbreaking work and dedication of our talented team in developing cutting-edge technologies that have the potential to revolutionize healthcare. This recognition comes as a great honor to Immunis and reinforces our commitment to improving the lives of people around the world through our transformative, investigational secretome products.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit:

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.